Clinical Trials Logo

Clinical Trial Summary

The aim of the trial is to improve first-line treatment for early unfavorable cHL by introduction of the anti-PD-1 antibody Nivolumab with a truncated standard chemotherapy (AVD). The primary objective is to show efficacy of the two experimental treatment strategies. Secondary objectives are to further evaluate efficacy, show safety and feasibility and perform correlative studies.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03004833
Study type Interventional
Source University of Cologne
Contact
Status Active, not recruiting
Phase Phase 2
Start date February 21, 2017
Completion date December 2022

See also
  Status Clinical Trial Phase
Not yet recruiting NCT04952584 - Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes in Patients With Relapsed or Refractory CD30-Positive Lymphomas Phase 1
Not yet recruiting NCT04837859 - Phase II Trial of Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma Phase 2
Recruiting NCT03212404 - Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers Phase 1
Recruiting NCT04288726 - Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas Phase 1
Active, not recruiting NCT02684708 - Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents Phase 3
Active, not recruiting NCT03226249 - PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin Lymphoma Phase 2
Active, not recruiting NCT03739619 - Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Phase 1/Phase 2
Completed NCT03327571 - B-CD30 + Hodgkin Lymphoma International Multi-center Retrospective Study of Treatment Practices and Outcomes
Recruiting NCT03652441 - Consolidation Therapy With Brentuximab Vedotin After Allogeneic Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma Phase 2
Completed NCT02243436 - Brentuximab Vedotin in Pre-transplant Induction and Consolidation for Relapsed or Refractory Hodgkin Lymphoma Phase 1/Phase 2
Recruiting NCT04254107 - A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer Phase 1
Recruiting NCT02981914 - Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation Early Phase 1
Withdrawn NCT03205891 - Study of Brentuximab Vedotin Plus TAK228 for Relapsed/Refractory Classical Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma and Other CD30+Peripheral T-Cell Lymphomas Phase 1
Not yet recruiting NCT02808520 - Social Inequalities in the Participation and Activity in Children and Adolescents With Hodgkin-lymphoma N/A
Recruiting NCT02332668 - A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051) Phase 1/Phase 2
Recruiting NCT04858568 - Immune Responses to COVID-19 Vaccination in Lymphoma Patients
Not yet recruiting NCT03552003 - Study for Elderly (≥ 65 Years) Patients With Classical Hodgkin Lymphoma Undergoing CGA at Diagnosis
Recruiting NCT02824029 - Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Phase 2
Not yet recruiting NCT04510636 - Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma Phase 2
Recruiting NCT02815137 - Detection and Prognostic Value of Recurrent XPO1 Mutations of Patients With Classical Hodgkin Lymphoma N/A